Gilead new drug selonsertib abandons PAH and DKD and focuses on Nash research and development

Source: Biovalley 2016-10-24 pharmaceutical giant Gilead recently released a mixed result The new drug gs-4997 (selonsertib) developed by the company failed to reach its clinical end point in two phase II clinical studies of pulmonary hypertension (PAH) and diabetic nephropathy (DKD) After analyzing the data in detail, the company finally decided to abandon the development of gs-4997 in the above two diseases Unfortunately, however, gs-4997 has shown promise in the phase II clinical study of NASH Gs-4997 is an inhibitor of apoptosis signal regulated kinase-1 In a non blinded phase II study to treat Nash, the researchers found that the drug helped prevent fibrosis in the liver In this study, 72 patients with Nash were recruited The liver of these patients had moderate or even severe fibrosis The researchers compared the efficacy of the gs-4997 18mg and 6mg daily oral dose groups, as well as the efficacy of the above dose groups and Gilead's other drug, simtuzumab (SIM), in combination or alone After 24 weeks of treatment, the degree of liver fibrosis in 13 of the 30 patients in the 18 mg group was significantly reduced (from severe to moderate or from moderate to mild), and 8 of the 27 patients in the 6 mg group showed the same effect Only two of the 10 patients who received SIM were effective This result not only shows the future development direction of gs-4997, but also makes the prospect of SIM clear Previously, SIM failed in the clinical research of tumor treatment and idiopathic pulmonary fibrosis In the future, the company may turn its research focus to Nash field The company expects to release details of the clinical study next month In recent years, around the field of Nash therapy, many pharmaceutical giants have launched a fierce fight Faced with Nash's market share of US $40 billion, Geely Germany can't let it go The research data of gs-4997 will undoubtedly be the fuse to stimulate further competition in the field of therapy research and development However, it will take time for Gilead to test whether it can win as clean as it did in the hepatitis C drug market.